Most recently, Shen et al., constructed a liposome delivery system containing oxaliplatin and NLG919 (IDO1 inhibitor), to test the efficacy of this treatment in a mouse model of CRC, proposing an effective therapeutic approach for reversing the immunosuppressed tumor environment [168]. This evidence concerns the gene IDO1 and neoplasm.